D-I03

TargetMol
Product Code: TAR-T10936
Supplier: TargetMol
CodeSizePrice
TAR-T10936-1mg1mg£95.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10936-2mg2mg£106.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10936-5mg5mg£127.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10936-1mL1 mL * 10 mM (in DMSO)£132.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10936-10mg10mg£173.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10936-25mg25mg£309.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10936-50mg50mg£401.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T10936-100mg100mg£550.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
D-I03 is a selective RAD52 inhibitor with a Kd of 25.8 ?M. D-I03 specifically inhibits RAD52-dependent single-chain annealing (SSA) and D-loop formation, with IC50 of 5 ?M and 8 ?M, respectively. D-I03 inhibited the growth of BRCA1 and BRCA2 deficient cells and inhibited the formation of damage-induced RAD52 foci, but does not effect on RAD51 foci induced by Cisplatin.
CAS:
688342-78-1
Formula:
C23H36N6S
Molecular Weight:
428.64
Pathway:
Cell Cycle/Checkpoint; DNA Damage/DNA Repair
Purity:
0.9904
SMILES:
S=C(NC=1C=CC=2N=C(C=C(C2C1)C)N3CCN(CC)CC3)NCCN(CC)CC
Target:
DNA/RNA Synthesis

References

1. Huang F, et al. Targeting BRCA1- and BRCA2-deficient cells with RAD52 small molecule inhibitors. Nucleic Acids Res. 2016 May 19;44(9):4189-99. 2. Hengel SR, et al. Small-Molecule Inhibitors Targeting DNA Repair and DNA Repair Deficiency in Research and Cancer Therapy. Cell Chem Biol. 2017 Sep 21;24(9):1101-1119. 3. Sullivan-Reed K, et al. Simultaneous Targeting of PARP1 and RAD52 Triggers Dual Synthetic Lethality in BRCA-Deficient Tumor Cells. Cell Rep. 2018 Jun 12;23(11):3127-3136.